“Saliva Diabetes Diagnosis US FDA Clinical Trial 추진”…DYD to Hold Corporate Presentation on the 11th

DYD announced on the 7th that it will hold an investor relations (IR) meeting for major domestic and international institutions and individual investors at the Leaders Hall of the Yeouido Financial Investment Education Center on the 11th.

At this briefing, presentations on the saliva-based glycated albumin business and cosmetics business are scheduled. The company also plans to unveil the recently developed glycated albumin diagnostic kit on the same day.

Having recently replaced its management team entirely with bio experts, DYD established a bio division and declared its entry into the diabetes diagnostic market. The company has already completed the development of semiconductor wafers, a key component of the glycated albumin diagnostic kit, and is pushing forward with the establishment of large-scale production facilities. Additionally, it is preparing for approval from the U.S. FDA. To this end, it has pursued a business agreement with Montgomery County, Maryland, where the U.S. FDA headquarters is located.

DYD’s glycated albumin diagnostic kit is a product that enables diabetes diagnosis through saliva testing without blood collection, measuring glycated albumin in saliva within one minute. The testing process is simple and does not require blood sampling, significantly reducing the burden on patients. Moreover, it can reduce errors that may occur with conventional blood glucose measurement methods and allows for more frequent diagnosis, making everyday diabetes monitoring easier.

A DYD representative stated, “At the first investor relations meeting since the management change, we plan to explain DYD’s full-scale strategy to enter the bio market. As this event will be the first unveiling of the ‘saliva-based health screening kit’ that will present a new paradigm in health diagnostics, we ask for your great interest and participation.”

Meanwhile, according to the market research firm Global Information, the global diabetes diagnostic market was estimated at $21.91 billion (approximately 31.64 trillion KRW) last year, and Wise Guy Reports (WGR) forecasted that the diabetes diagnostic kit market will grow at an average annual rate of 7.58% until 2030.